Gender Differences Based on Either Ig V Gene Mutation Status or the Percentages of CD38+ B-CLL Cells
| . | Unmutated . | Mutated . |
|---|---|---|
| Male3-150 | 91.7% (22/24) | 52.2% (12/23) |
| Female3-150 | 8.3% (2/24) | 47.8% (11/23) |
| P = .0033-150 | ||
| Male:female ratio | 11.0:1 | 1.1:1 |
| ≥30% CD38+ B-CLL Cells | <30% CD38+ B-CLL Cells | |
| Male3-150 | 88.2% (15/17) | 52.6% (10/19) |
| Female3-150 | 11.8% (2/17) | 47.4% (9/19) |
| P = .0313-150 | ||
| Male:female ratio | 7.5:1 | 1.1:1 |
| . | Unmutated . | Mutated . |
|---|---|---|
| Male3-150 | 91.7% (22/24) | 52.2% (12/23) |
| Female3-150 | 8.3% (2/24) | 47.8% (11/23) |
| P = .0033-150 | ||
| Male:female ratio | 11.0:1 | 1.1:1 |
| ≥30% CD38+ B-CLL Cells | <30% CD38+ B-CLL Cells | |
| Male3-150 | 88.2% (15/17) | 52.6% (10/19) |
| Female3-150 | 11.8% (2/17) | 47.4% (9/19) |
| P = .0313-150 | ||
| Male:female ratio | 7.5:1 | 1.1:1 |
Statistically significant difference in gender distribution between the unmutated and mutated groups and between the ≥30% CD38+ and <30% CD38+ groups (2-tailed Fisher’s Exact test).